Regula Helps Austrian Municipalities Facilitate ID Verification and Processing
10.9.2024 08:00:00 CEST | Business Wire | Press release
Municipal registration offices across Austria have integrated advanced document readers Regula 7024M to automate and secure identity verification processes. This initiative is part of the “Sicheres Meldeamt” (secure registration office) project, launched by the Federal Ministry of Internal Affairs of Austria.
In Austria, the municipal registration office (Meldeamt) plays a crucial role in the administrative process for both citizens and residents. It's where individuals are required to register their place of residence, which is an essential part of living in Austria. However, its role extends beyond mere registration; it facilitates a smooth transition for individuals moving within or to Austria, granting them access to public services and contributing to orderly municipal management.
The need for modernization
Traditionally, the verification of identity documents in Austrian registration offices has been based predominantly on manual work, which requires a certain level of expertise, is time-consuming and prone to errors. Recognizing the need for more efficient and hurdle-free operations, theMinistry of Internal Affairs has launched the “Sicheres Meldeamt” initiative and has offered registration offices a new approach to automate identity document reading and verification.
The solution
To realize the “Sicheres Meldeamt” project across the whole country, cooperation with IT service providers to Austrian registration offices was initiated. Among these providers are Kufgem, Gemdat OÖ, PSC, Comm-Unity EDV, Gemdat NÖ, and others. They have offered to equip registration offices with compact desktop document readers Regula 7024M.
Regula’s devices were chosen because they feature advanced OCR technology tailored for identity documents, MRZ and barcode reading modules, and multiple light sources. It helps Regula 7024M accurately identify various data types, including engraved and embossed text. Additionally, the device comes equipped with an RFID chip reading module to enable the verification of biometric documents. By performing extensive data cross-checks, Regula 7024M helps identify any possible inconsistencies in personal information that may indicate fraud.
First results and future prospects
The pilot projects in cities like Linz, Telfs, and Sankt Pölten have shown significant improvements in the registration processes. With Regula 7024M, documents are processed instantaneously, significantly reducing the manual workload and virtually eliminating human error.
Christoph Heichinger, Ministerial Councillor from the Central Office of the Federal Ministry of Internal Affairs of Austria and one of the project managers of the “Sicheres Meldeamt” project, stated, "The digital enhancement of the registration process allows registration offices to create effective protection mechanisms against the unauthorized use of registration confirmations. This is achieved by using high-quality passport and document readers for verifying documents."
Now, the “Sicheres Meldeamt” project is going to be extended to other registration offices in Austria.
“We are immensely proud to see our document readers streamlining and securing ID processing in Austrian registration offices. Regula 7024M is a powerful tool capable of transforming the daily operations of border controls and immigration services. This initiative sets a new nationwide benchmark for identity verification and we look forward to continuing our support for the ‘Sicheres Meldeamt’ project as it expands across the country,” said Maris Kaminskis, Executive Director at Regula Europe.
To learn more about Regula’s involvement in the “Sicheres Meldeamt” project, please read the success story.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909830261/en/
Contacts
Kristina – ks@regulaforensics.com
Kristina – ks@regulaforensics.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom